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Executive Summary 
Background and research question: 
Selective internal radiotherapy (SIRT) is a treatment option for patients 
with primary and secondary liver malignancies, such as hepatocellular car-
cinomas (HCC) or metastases from colorectal cancer (mCRC), neuroendo-
crine tumours or breast cancer. This technique involves the injection of ra-
dionuclides (e.g. jodine-131, rhenium-188, yttrium-90) directly into the liver 
artery. If yttrium-90 is used, small particles the so called microspheres are 
used to deliver the radioactive substance. Two yttrium-90 products are 
commercially available: resin-microspheres (SIR-Spheres®) and glass-
microspheres (TheraSphere®). Due to differing blood supply of healthy liver 
tissue and tumour, the microspheres lodge directly in the tumour and can 
deliver radiation predominantly to the tumour.  
The research question of this review was whether SIRT using yttrium-90 mi-
crospheres is an efficacious and safe therapy in comparison to other treat-
ment options for non-resectable, non-ablatable HCCs and mCRC.  
Methods: 
A systematic literature search, in addition to a hand search and literature 
provided by the manufacturers as well as the applicant resulted in 900 refer-
ences overall. 
Inclusion criteria for efficacy were prospective controlled trials and for safe-
ty prospective studies with ≥50 patients.  
Results: 
2 studies, both reporting on TheraSphere®, were included for efficacy of 
SIRT for the treatment of HCC. One trial showed improvements in median 
overall survival for the SIRT group, but this might be explained due to dif-
ferent baseline characteristics of the two groups. Another study, which in-
cluded 28 patients, showed only partly improved results for quality-of-life. 
For efficacy of SIRT for mCRC, 3 randomized controlled trials, all using 
SIR-Spheres®, were included but a judgment on efficacy was hampered as 
results deviated, different comparators were used and additional therapies 
were allowed.  
Data on safety was considered in 8 studies overall. It seems that careful pa-
tient selection is crucial for a safe treatment with SIRT. Overall, the safety 
profile of this intervention is acceptable.  
Conclusion and recommendation: 
The evidence for TheraSphere® for the treatment of HCC does not currently 
allow a definite statement on efficacy. An inclusion in the catalogue of bene-
fits is not currently recommended.  
The evidence indicates that treatment of mCRC with SIR-Spheres® is more 
efficacious and as safe as other treatment options. An inclusion in the cata-
logue of benefits is therefore recommended with restrictions and a re-
evaluation should be conducted in 2015.   
 
SIRT: radionuclides 
injected directly into 
liver artery 
2 yttrium-90 products 
commercially available: 
SIR-Spheres®, 
TheraSphere® 
research question: SIRT 
for hepatocellular 
carcinoma and liver 
metastases from 
colorectal cancer 
overall 900 references 
2 efficacy studies for 
TheraSphere®… 
3 for SIR-Spheres® 
for safety another 8 
studies included 
TheraSphere® not 
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SIR-Spheres® for mCRC 
recommended with 
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1 Technology  
1.1 Background 
1.1.1 Primary liver cancer 
Primary liver cancer comprises several different entities, such as hepatocel-
lular carcinomas (HCC) and cholangiocarcinomas. Of those, HCC is the 
most common form of malignant hepatobiliary diseases and it is the third 
most common cause of cancer-related death worldwide [1]. Risk factors in-
clude hepatitis B and/or hepatitis C virus infections, alcohol abuse or cir-
rhosis [1, 2]. On average men are 3.7 times more frequently affected than 
women and median age at diagnosis ranges from between 50 and 60 years 
[1]. In Austria, 785 patients were newly diagnosed with liver cancer in 2008 
[3].    
Because the liver has a large functional reserve and there are few specific 
symptoms associated with HCC, HCCs are usually diagnosed at a late stage 
of the disease. This results in a median survival of 6 to 20 months after diag-
nosis [1] and a 5-year survival rate of only 3% to 5% [4]. To establish prog-
nosis, many different systems exist (e.g. TNM-system, the Okuda-system 
and the CLIP score), but none of them is commonly accepted. However, all 
of these systems incorporate four characteristics crucial for survival: the se-
verity of underlying liver disease, the size of the tumour, the extension of the 
tumour into adjacent structures, and the presence of metastases [5].  
Potentially curative therapies include resection of the liver if function is ad-
equate, or, if cirrhosis is more advanced, liver transplantation [4]. But these 
therapies are often not an option, either because of the extent of the tumour, 
the location of the tumour or because of compromised liver function or re-
duced performance status [2].  
Treatment options for un-resectable HCCs are local non-surgical methods 
like ablation techniques or embolization. Radiofrequency ablation (RFA) 
and percutaneous ethanol injection belong to the first category. Both tech-
niques induce tumour necrosis, either by using an alteration in temperature 
(radiofrequency ablation) or by exposing the tumour to chemicals (percuta-
neous ethanol injection). RFA is usually indicated for singular tumours with 
a diameter of <4 cm [6].  
Multiple tumours in the liver or larger tumours can be treated using em-
bolizing methods: embolizing particles ± chemotherapy or iodine 131- la-
belled lipiodol are directly injected into the liver artery [2]. Transarterial 
chemoembolisation (TACE) is most often used for large un-resectable HCCs 
which cannot be treated with other techniques such as RFA [7]. In contrast 
to bland embolization (synonymous: transarterial embolization) where only 
embolic particles are injected in the hepatic artery, TACE includes the addi-
tional injection of a chemotherapeutic drug [2]. Systemic chemotherapy is 
not usually used for the treatment of HCC, because this cancer is most often 
refractory to chemotherapy and tolerability of this toxic therapy is limited 
by any underlying liver dysfunction [1]. However, sorafenib, a molecular 
targeted therapy,  offers a systemic treatment option and is recommended 
for un-resectable tumours, for patients not eligible for surgery due to co-
hepatocellular 
carcinoma 3rd most 
common cause of 
cancer-related death 
risk factors: hepatitis, 
alcohol,… 
most often diagnosed at 
late stage of disease 
median survival of 6-20 
months 
surgery and liver 
transplantation are 
potentially curative 
treatment options, but 
only rarely an option 
other options: local non-
surgical methods or 
embolization 
multiple tumours most 
often treated with 
transarterial 
chemoembolisation 
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morbidities or performance status, or for patients with metastatic disease 
[2].  
1.1.2 Liver metastases  
Liver metastases from primary tumours are very common, including metas-
tases from breast cancer, neuroendocrine tumours or pancreatic cancer [4]. 
As 50% of all patients suffering from colorectal cancer (CRC), which is the 
third most common cancer in women and the fourth in men, will eventually 
develop metastases in the liver, hepatic metastases from CRC are very fre-
quent [4]. 5-year survival rates of patients diagnosed with liver metastases 
are less than 5% [4].  
If metastases are confined to the liver, patients might be cured with surgical 
resection [8]. But similar to HCCs, only the minority of patients, that is less 
than 10% with metastatic disease, are candidates for surgery, either because 
of the tumour size, the location of the tumour or due to liver dysfunction. In 
this palliative setting, systemic chemotherapy (e.g. FOLFOX = oxaliplatin, 
leucovorin, 5-fluorouracil (5-FU), capecitabine or FOLFIRI = irinotecan, 
leucovorin, 5-FU, capecitabine ) [9] is then the standard therapy for metas-
tatic CRC (mCRC). For these patients, local therapies offer an alternative 
treatment option to systemic chemotherapy [8]. These local therapies in-
clude the above mentioned ablation techniques such as RFA, or, hepatic ar-
terial chemotherapy (HAC)[8]. During HAC, chemotherapeutic drugs are 
injected directly into the liver artery which allows higher concentrations of 
the drug in the liver than with systemic chemotherapy.  But, in order to de-
lay disease progression outside the liver, HAC might also be combined with 
systemic chemotherapy [8]. 
1.2 Description of the intervention  
„Selective Internal Radiotherapy“(SIRT), also called radioembolization, is a 
technique which specifically delivers radiation to hepatic malignancies. The 
underlying rationale is that healthy liver tissue is connected to the portal 
vein, whereas malignancies are mostly supplied by the liver artery [8, 10].  
Using a catheter, or a permanent implanted liver port [11], several radionu-
clides such as yttrium-90 (Y-90), jodine-131 or rhenium-188 can be delivered 
into the hepatic artery [12]. In the case of Y-90, two products are commer-
cially available (see Table 1.2-1), made either of resin (SIR-Spheres®) or 
glass (TheraSphere®). These radioactive particles, the so called micro-
spheres, are delivered into the hepatic artery and get trapped in the capillary 
bed [10, 13]. Y-90 is a pure β-emitter and has a mean tissue penetration of 
2.5mm [10]. Radiation can therefore be delivered predominantly to the tu-
mour while simultaneously sparing normal liver tissue, allowing higher ra-
diation doses than conventional radiotherapy [10]. Requirements for the 
targeted delivery are an exact positioning of the catheter and a pre-
therapeutic dosimetry to exclude shunting to the extrahepatic circulation. 
 
colorectal carcinomas 
metastasize to liver in 
50% 
non-resectable 
metastases most often 
treated with systemic 
chemotherapy 
other methods: hepatic 
arterial chemotherapy 
SIRT = radionuclides 
directly injected into 
liver artery 
2 Y-90 products are 
commercially available: 
SIR-Spheres®, 
TheraSphere® 
radiation predominately 
delivered to liver, 
therefore higher 
radiation doses possible 
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Table 1.2-1: Characteristics of commercially available Y-90 microsphere 
products [4, 10, 12]:  
Brand name SIR-Spheres® ThereSphere® 
Matrix material resin glass 
Diameter (μm) 20 - 60  20 - 30 
Activity/sphere (Becquerel) 50  2,500 
Average number of particles de-
livered  
40-60 million 1.2-8 million 
Activity delivered depending on body surface ar-
ea and tumour volume 
depending on the target dose 
and the patient’s liver mass 
Maximal prescribed dose (Giga 
Becquerel) 
3 20 
Licensed in Europe yes yes 
 
Both products are approved in Europe [12], but in the US, SIR-Spheres ® are 
only approved in combination with adjuvant HAC with floxuridine for the 
treatment of un-resectable liver metastases from primary CRC since 2002 
[14]. TheraSphere® is approved under the humanitarian device exemption 
for radiation treatment or as neoadjuvant therapy prior to surgery for pa-
tients with un-resectable HCC since 1999 [15]. The device exemption was 
expanded to patients suffering from HCC who additionally have a partial or 
branch portal vein thrombosis in January 2007 [16].  
Basic requirements for patients deemed eligible for SIRT are an adequate 
liver function (e.g. bilirubin ≤2mg/dl, liver enzymes < 5 times upper nor-
mal limit) and a liver-dominant tumour burden [12]. A detailed patient his-
tory is necessary, because previous chemotherapy might be associated with 
higher rates of complications associated with SIRT [17, 18]. Due to the em-
bolic effect of SIR-Spheres®, portal vein thrombosis [4] has to be excluded 
prior to therapy with resin-microspheres. Moreover, aberrant vessels to the 
gastrointestinal tract which could distort the targeted delivery of the micro-
spheres directly to the tumour and which would lead to radiation exposure 
of organs such as the gallbladder, or the stomach, need to be embolized be-
fore SIRT [4, 10, 13]. In addition, excessive exposure of the lungs to radia-
tion has to be avoided in order to reduce adverse events such as radiation-
induced pneumonitis.  
Proposed eligibility criteria for SIRT are thus:    
 un-resectable primary or metastatic hepatic disease with liver domi-
nant tumour burden and life-expectancy ≥ 3 months 
 an acceptable lung shunt fraction (≤20 Gray for resin, ≤30 Gray for 
glass microspheres) 
 an adequate liver function  
 absence of portal vein thrombosis (only SIR-Spheres ®) 
 a good performance status [19-21]. 
Therefore a rigid pre-treatment work-up is necessary: pre-treatment blood 
work to evaluate the liver function [10] and a CT/MRI scan to assess the 
tumour volume and the extent of extrahepatic disease and to exclude portal 
vein thrombosis are required [22]. In addition, an angiogram is necessary to 
licensed in Europe and 
the US 
patient selection for 
SIRT 
rigid pre-treatment 
work-up necessary 
Selective internal radiotherapy 
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map out the blood supply to the liver and thus ensure the delivery route [10, 
22]. To avoid excessive shunting of the radioactive microspheres to the 
lungs, a scan with a nuclear tracer (technetium 99 labelled macroaggregated 
albumin) has to be performed [4, 22].  
If the patient has been found to be eligible for SIRT, a catheter is placed un-
der fluoroscopic control in the hepatic artery through an incision in the 
groin and the microspheres are then injected in the artery [23]. Another op-
tion to administer the microspheres is via a permanent hepatic port. Usu-
ally, only one treatment is delivered, but especially in patients with HCC 
and a compromised liver reserve, several treatments can be administered 
[22]. Even though the intervention can be performed as an outpatient proce-
dure [10, 23, 24], patients are usually discharged  2 days after the interven-
tion in Austria and Germany [20].  
In summary, treatment delivery and planning of SIRT requires a multidis-
ciplinary team of experts including (interventional) radiologists, nuclear 
medicine specialist, oncologists and surgeons and it is thus a resource in-
tense intervention. 
1.3 Indication and therapeutic aim 
As already mentioned above, SIRT is indicated for patients with large, un-
resectable hepatic primary cancer or metastatic cancer and liver-dominant 
tumour burden and a life expectancy ≥ 3 months [10, 25]. This includes, be-
sides HCC and mCRC, many other tumours such as cholangiocarcinomas or 
metastases from breast cancer, pancreatic cancer or neuroendocrine tumours 
[16, 26].  
For the most common malignancies (HCC, mCRC) many indications exist.  
More specifically for HCC, SIRT might also be used:  
 for non-resectable, non-ablatable HCCs 
 as bridge to transplant by allowing more time to wait until transplan-
tation or, 
 to downstage the tumour either to within transplant criteria if pa-
tients do not fulfil transplantation criteria initially, or to enable resec-
tion or to allow partial liver hepatectomy [7, 17, 23, 27].  
For mCRC, several indications are also possible: 
 after failure of first-line chemotherapy 
 in combination with (systemic) chemotherapy as first-line therapy 
 as salvage therapy after failure of several lines of chemotherapy for 
patients with mCRC [25, 28]. 
Therefore, SIRT therapy has, besides some exceptions (downstaging), a pal-
liative intention with the therapeutic aim of prolonging survival, delaying 
disease progression and maintaining or achieving good quality-of- life 
(QoL).  
microspheres injected 
into liver artery using a 
catheter 
in-patient stay for 2 
days 
SIRT for primary liver 
cancer and metastatic 
liver cancer, life 
expectancy  ≥ 3 months 
different indications for 
HCC… 
and mCRC possible 
Technology  
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1.4 Estimated volumes of services and costs 
Based on the documents submitted by the applicant, about 20 procedures 
are performed each year at this hospital. No estimates are available for Aus-
tria in general. Since treatment planning and delivery of SIRT requires a 
multidisciplinary team and a department for nuclear medicine and interven-
tional radiology, only specialised tertiary care hospitals qualify.  
No information regarding the costs of any microsphere product was men-
tioned on the application submitted, but some evidence from Germany sug-
gests a price of € 14,000.- for the microsphere products [20].  
 
according to applicant: 
20 procedures/year 
 
 
no cost estimates 
submitted, but some 
evidence that cost 
might be about € 14,000 
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2 Literature search and selection of 
literature 
2.1 Research question 
Based on the application submitted to the Ministry of Health (MoH) the re-
search question was: 
Does SIRT using Y-90 microspheres in patients with non-resectable, non-
ablatable primary liver cancer or with metastatic liver tumours lead to better 
clinical outcomes and fewer adverse effects than alternative treatment op-
tions? 
After scoping the literature, this overall research question was narrowed 
down to the two most common malignancies1. The research questions were 
thus:  
1. Does SIRT using Y-90 microspheres in patients with non-
resectable, non-ablatable HCC lead to improved clinical outcomes 
(survival, progression, quality of life, tumour response) and fewer 
adverse events than TACE, HAC, sorafenib or best supportive care?   
2. Does SIRT using Y-90 microspheres in patients with non-
resectable, non-ablatable liver metastases from colorectal carci-
noma lead to improved clinical outcomes (survival, progression, 
quality of life, tumour response) and fewer adverse events than sys-
temic chemotherapy, HAC or best supportive care?   
2.2 Inclusion criteria 
Inclusion criteria for the identification of relevant references are displayed 
in table 2.2-1. 
Table 2.2-1: Inclusion criteria 
Population non-resectable, non-ablatable  HCC/ mCRC  
Intervention selective internal radiotherapy using Y-90  microspheres 
( ± systemic chemotherapy or HAC) 
Control HCC: 
  TACE, HAC 
 Sorafenib 
 best supportive care 
mCRC: 
 HAC 
 systemic chemotherapy 
 best supportive care 
Safety: any 
                                                             
1 Due to the large number of entities, methodological and feasibility considerations 
necessitated to restrict the research question.  
PICO-question 
efficacy/safety of SIRT 
for HCC 
efficacy/safety of SIRT 
for mCRC 
study inclusion criteria 
Selective internal radiotherapy 
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Outcomes  • survival 
• quality-of-life  
• progression  
• tumour response 
• adverse events 
Study design Efficacy: prospective controlled studies 
Safety: prospective controlled studies, prospective stud-
ies ≥ 50 patients 
 
2.3 Literature search 
A systematic literature search was conducted between 28.-31.01.2011 in the 
following databases:  
 Medline via Ovid 
 Embase  
 Cochrane Central Register of Controlled Trials 
 NHS-CRD-HTA (INAHTA) 
 
The systematic search was not limited to specific publication dates and 
yielded after deduplication 852 references. The detailed search history can 
be found in the appendix.    
The manufacturers of the two technologies (SIR-Spheres®, TheraSphere®) 
submitted an additional 9 relevant studies, a hand search identified 136 ref-
erences and the applicant submitted 4 articles. Overall after deduplication, 
900 hits/studies were found.  
. 
 
systematic literature 
search in databases and 
websites  
literature search yielded 
852 hits 
hand search: 136 hits 
overall 900 references  
Literature search and selection of literature 
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Records identified through data-
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Additional records identified 
through other sources  
(n = 136 hand search, n = 9 refer-
ences submitted by manufactur-
ers, n = 4 submitted by applicant)   
Records after duplicates removed
(n = 900) 
Records screened 
(n = 900) 
Records excluded 
(n = 744)    
Not available: n =3 
Not relevant: n = 741         
Full-text articles assessed for eli-
gibility 
(n = 156) 
Full-text articles excluded, 
with reasons 
(n = 143 ) 
Background lit.: n = 18 
Design: retrospective n = 53 
Wrong outcome: n = 3 
Wrong population: n = 12 
(<50 patients) 
Insufficient information: n = 
42 (abstracts) 
Different intervention: n = 3 
Other research question: n = 
4 
Not English/German: n = 6 
Duplication of results: n = 2 
Studies included in qualitative 
synthesis 
(n = 13) 
Efficacy: 
HCC = 2 
mCRC = 3 
 
Safety: n = 8 
2.4 Literature selection 
900 references were considered for inclusion overall. The literature selection 
was done by two independent researches. In case of disagreement a third re-
searcher was involved to establish consensus. The study selection process is 
displayed in figure 2.4-1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4-1: Literature selection process (PRISMA Flow Diagramme) 
 
literature selection  
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3 Study quality  
Assessment of the internal validity of studies was done by two researchers 
independently. Different results were discussed in order to achieve consen-
sus. A third person was involved in cases of uncertainty. The internal man-
ual of the LBI-HTA describes the quality criteria in detail [29]. 
4 Data extraction 
Data extraction was done by a single researcher. A second researcher inde-
pendently double-checked the data for correctness and completeness. 
4.1 Description of study results 
13 studies were included overall [30-42]. For efficacy of SIRT for HCC, two 
studies on TheraSphere® were found [30, 31]; for safety 5 studies  [32-36] 
were included, where all but 1 [36] assessed TheraSphere®.  
3 randomized controlled trials (RCTs), all using SIR-Spheres® were identi-
fied for efficacy of SIRT for mCRC [37-39]. Data on safety were extracted 
from 3 publications [40-42]. Of those, 2 used SIR-Spheres® [40, 41] und 1 
[42] TheraSphere®. 
HCC: 
2 comparative and prospective studies using TheraSphere® were found for 
efficacy (see table 4.1-1) [30, 31].  
The study conducted by Carr et al. [30] enrolled two sequential cohorts: the 
first, which was recruited between 1992 and 2000, consisted of 691 patients 
whom were treated with TACE. The second cohort (2000 – 2005) comprised 
99 patients treated with TheraSphere®. The second non-randomized study 
[31] assessed QoL in 28 patients overall.  
Outcomes which were considered in this review included: 
 Survival: median overall survival (OS), survival rates 
 Progression: time to disease progression (TTP) 
 Tumour response: partial response (PR) , complete response (CR), 
stable disease (SD), progressive disease (PD) 
 Quality-of-life (QoL) 
 Adverse events (AEs) 
 
 
 
study quality 
assessment 
data extraction  
13 studies included 
overall 
2 prospective controlled 
trials for efficacy for 
HCC 
outcomes considered 
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Outcomes which were considered as relevant for formulating the recom-
mendations are: 
 OS 
 TTP 
 PR, CR, SD, PD 
 QoL 
 Adverse events: adverse events grade ≥3, treatment-related deaths 
 
OS and QoL were chosen because the therapeutic aim in this setting is to 
prolong life and/or to increase QoL. Time to disease progression and tumour 
response as measured by tumour area are clearly surrogate outcomes but a 
change in tumour size is an important outcome if tumours can be down-
sized, consequently allowing liver transplantation in previously ineligible 
patients. Time to disease progression is relevant if SIRT is used as a bridge-
to-transplant.   
mCRC: 
3 RCTs [37-39], all using SIR-Spheres®, were included for efficacy of SIRT 
for the treatment of mCRC. The study characteristics and the results are 
summarized in table 4.1-3.  
All 3 comparative trials evaluated SIR-Spheres® for mCRC and can essen-
tially be regarded as industry-sponsored [37-39]. Sample size ranged from 21 
[37] patients to 70 patients [38]. 2 trials [37, 39] compared SIR-Spheres® + 
systemic chemotherapy to systemic chemotherapy alone, whereas the third 
trial used HAC as a comparator [38]. Enrolled patients differed between the 
trials as they included untreated [37], as well as patients previously treated 
for their metastatic disease [39]. Similarly, presence of extrahepatic disease 
at time of randomisation was an exclusion criterion in two studies [38, 39], 
whereas van Hazel et al. [37] also included patients with extrahepatic dis-
ease.  
Outcomes which were considered in this review included: 
 Survival: OS , survival rates 
 Progression: TTP, time to hepatic disease progression (TTHP) 
 Tumour response: CR, PR, SD, PD, serum CEA changes 
 QoL 
 Adverse events 
Outcomes which were considered as relevant for formulating the recom-
mendations are: 
 OS 
 TTP 
 PR, CR, SD, PD 
 QoL 
 Adverse events grade ≥3, treatment-related deaths 
3 RCTs for efficacy for 
mCRC 
outcomes considered 
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Improvements in OS and QoL are again the most important outcomes for 
patients with mCRC. Tumour response and TTP are surrogate parameters 
but they can provide some information on the intervention’s activity.  
Safety:  
Safety issues related to SIRT concerning HCC was the topic of  5 uncon-
trolled studies [32-36] (see Table 4.1-2). In 4 studies, glass-microspheres 
were used [32-35], whereas only one used resin microspheres [36]. Sample 
sizes ranged from 71 [36] to 291 patients [33].  
3 studies which met our inclusion criteria were found which assessed mCRC 
[40-42] (see table 4.1-4). SIR-Spheres ®  were used in 2 [40, 41] and TheraS-
phere® in 1 study [42]. Sample size ranged from 50 [40] to 140 patients [41] 
and all trials evaluated patients previously treated with chemotherapy.  
 
 
 
 
 
for safety: 8 
uncontrolled trials, 5 for 
HCC, 3 for mCRC 
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Table 4.1-1: Comparative studies for efficacy of SIRT for the treatment of HCC  
Author, Year [Reference]  Carr 2010 [30] Steel 2004 [31] 
Country USA USA 
Sponsor US National Institutes of Health American Cancer Society 
Study period C: 1992 – 2000 
I: 2000 - 2005 
NR 
I(ntervention) glass microspheres glass microspheres 
Indication unresectable HCC unresectable HCC 
Administration of intervention median dose: NR; single dose TheraSphere, 30% 
received a 2nd treatment 
single dose TheraSphere 
C(omparator) TACE (125mg/m2 of body surface area cisplatin) + 
Gelfoam sponge particles/biospheres 
HAC (cisplatin 125mg/m2 every 6 weeks) 
Study design open-label, cohort study prospective, non-randomized study 
Number of patients  790, I 99 vs C 691 28, I 14 vs C 14 
Mean age of patients     NR 59 
Patient characteristics male: I 70% vs C 75% 
PVT: I 28% vs C 42% 
male: I 64% vs C 79% 
Inclusion unresectable HCC, not amenable to RFA, hepatic 
transplantation 
HCC 
Exclusion ECOG PS 0-1 current suicidal ideation, current psychosis, health 
too poor to complete questionnaire 
Follow up (months) NR NR 
Outcome    
Median survival I 11.5 months (95%CI 8 – 16 months) vs C 8.5 
months (95%CI 8 – 10 months), p< 0.05 
NR 
Survival rate NR NR 
Tumour response measured by tu-
mour area  
(criteria used) 
WHO - 
 CR: I 3% vs C 5% 
PR: I 38% vs C 55% 
SD: I 35% vs C 29% 
PD: I 23% vs C 11% 
NR 
Median time to disease progression NR NR 
QoL NR FACT-Hep instrument: 
3 months follow-up: I vs C functional well-being 
(p<0.001), overall health-related quality of life 
(p<0.001)   
6 months follow-up: I vs C: higher functional well-
being (p<0.04)  
Treatment related deaths NR NR 
overall AEs NR NR 
Grade 1-2 NR NR 
Grade ≥3 NR NR 
Notes difference in survival may be explained by the se-
lection of patients who had milder disease in the 
SIRT group 
 
 
Abbreviations used: PVT = portal vein thrombosis, ECOG PS = Eastern Cooperative Oncology Group Performance 
Status, NR = not reported, CI = confidence interval, WHO = World Health Organisation, FACT-Hep = Func-
tional Assessment of Cancer Therapy- Hepatobiliary 
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Table 4.1-2: Uncontrolled studies for safety of the efficacy of SIRT for the treatment of HCC 
Author, Year  
[Reference] 
Kulik 2008 [32] Salem 2010 [33] Hilgard 2010 [34] Atassi 2008 [35] Lau 1998 [36] 
Country  USA USA Germany  USA Hong Kong 
Sponsor MDS Nordion 
(grants to indi-
vidual authors) 
MDS Nordion (research 
support to individual 
authors)  
NR one author acts as 
an advisor to MDS 
Nordion 
NR 
Study period NR January 2004 – Decem-
ber 2008 
November 2006 – 
March 2009 
2001 - 2006 October 1992 – Decem-
ber 1995 
Intervention  glass micro-
spheres 
glass microspheres glass microspheres glass microspheres resin-based microspheres
Indication HCC unresectable HCC unresectable HCC unresectable HCC unresectable  HCC 
Administration of in-
tervention 
median dose 134 
Gy, 1 -3 treat-
ments 
median dose 103 Gy, 
mean 1.8 treatments 
mean dose 120 Gy, 
mean 1.5 treatments 
NR median dose 5.6 to 13 GY, 
1 – 5 treatments 
Study design open-label, phase 
II 
prospective longitudi-
nal cohort study 
observational cohort 
study 
prospective safety 
study 
prospective observatio-
nal study 
Number of patients  108 291 108  190 71 
Mean age of patients    
(years) 
69 65 65  NR 55 median 
 
Patient characteristics male: 69% 
PVT: 34% 
Child Pugh A/B: 
54%/27% 
male: 77% 
PVT: 43% 
previously treated: 13%
Child Pugh A/B: 
45%/52% 
male: 80% 
PVT: 31% 
previously treated: 
38% 
Child-Pugh A: 77% 
BCLC stage B/C: 
47%51% 
 
NR male: 87% men 
previously treated: 28% 
Inclusion ECOG ≤2  ECOG ≤2, extrahepatic 
disease, portal vein 
thrombosis 
HCC of BCLC C tu-
mour stage, or with 
BCLC A/B if not eligi-
ble for selective TACE, 
ECOG ≤2) 
ECOG 0-3 Karnofsky PS >70% 
Exclusion significant extra-
hepatic disease 
NR extrahepatic disease  life expectancy <3 
months 
extrahepatic disease 
Follow up (months) NR 31 months NR laboratory follow-up 
>300 days 
NR 
Outcomes       
Median survival 
(months) 
193 – 670 days 
(dependent on 
presence of portal 
vein throm-
bis/location of 
portal vein 
thrombosis, pres-
ence of cirrhosis) 
2. 5 months to 47.4 
months (dependent on 
staging based on UN-
OS, Child-Pugh, PVT, 
tumour stage) 
16.4 months (95%CI 
12.1 months to NR) 
NR 9.4 months (range 1.8 to 
46.4 from diagnosis) 
Survival rate (%) NR NR  at 1 year: 59% NR NR 
Tumour response 
measured by tumour 
area (criteria used) 
WHO WHO RECIST _ - 
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Author, Year  
[Reference] 
Kulik 2008 [32] Salem 2010 [33] Hilgard 2010 [34] Atassi 2008 [35] Lau 1998 [36] 
 PR 42% 
CR: 0% 
SD: 35% 
PD: 23% 
overall response rate: 
42% 
30/60/90 days after 
treatment: 
CR or PR: 
3%/10%/16% 
SD: 90%/80%/74% 
PD: 7%/10%/10% 
NR NR 
Median time to dis-
ease progression 
NR 7.9 months  
(95% CI 6.0 to 10.3 
months) 
10.0 months  
(95% CI 6.1-16.4 
months) 
NR NR 
QoL NR NR NR NR NR 
Treatment-related 
deaths (%) 
1 % (1/108) 0% 0% 0% 1% (1/71) 
AEs overall with/without cir-
rhosis: elevated 
bilirubin: 
40%/4% 
ascites: 18%4% 
hepatic encepha-
lopathy: 4%/0% 
NR NR symptomatic and 
asymptomatic tox-
icities: 15% 
low grade fever 14% 
nau-
sea/vomiting/abdominal 
pain: 17% 
Grade 1 – 2  NR fatigue: 57% 
diar-
rhoea/nausea/vomiting/
abdominal 
pain/anorexia: 2% - 
23% 
elevated liver enzymes: 
55% - 77% 
fatigue syndrome: 
61% 
abdominal pain: 56% 
NR NR 
Grade ≥3 with/without cir-
rhosis: elevated 
bilirubin: 2% - 
26%/0% - 4% 
ascites: 15%/4% 
hepatic encepha-
lopathy: 1%/- 
ascites: 4%/- 
 
elevated liver enzymes: 
4% - 19%  
 
lymphopenia: 11-60%
bilirubin toxicities: 3-
20% 
elevated liver en-
zymes:  
2%- 7% 
 
0% 
Notes  34% received treat-
ment with curative in-
tent after SIRT 
AEs grade 3/4 depend-
ing on values at base-
line 
 6% (4/71) became re-
sectable 
 
Abbreviations used: Gy = Gray, PVT = portal vein thrombosis, ECOG = Eastern Cooperative Oncology Group, PS 
= Performance  Status, BCLC = Barcelona Liver Cancer Clinic NR = not reported, CI = confidence interval, WHO 
= World Health Organisation, UNOS = United Network for Organ Sharing, RECIST = Response Evaluation Crite-
ria In Solid Tumors, HRQL= health related quality of life 
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Table 4.1-3:  Comparative studies for efficacy of SIRT for the treatment of mCRC  
Author, Year  
[Reference]  
Van Hazel 2004 [37] Gray 2001 [38] Hendlisz 2010 [39] 
Country Australia Australia Belgium 
Sponsor Sirtex Medical Limited Sirtex Medical Limited Sirtex Medical Limited 
Study period NR 1991 - 1997 December 2004 – November 2007 
Intervention  resin microspheres + systemic 
chemotherapy  
(5-fluorouracil 425mg/m2/day  + 
leucovorin 20 mg/m2/day for 5 
consecutive days every 4 weeks) 
resin microspheres + HAC  
(12 day cycles 0.3 mg/kg/day floxuridine 
for 18 cycles) 
resin microspheres + systemic che-
motherapy 
(5-fluorouracil 225mg/m2/days for 
14 consecutive days, followed by 5-
fluorouracil 300mg/m2/day for 14 
days every 3 weeks) 
Tumour stage 1st line therapy 1st- 2nd  line therapy salvage therapy 
Administration of in-
tervention 
single dose of resin microspheres, 
mean activity 2.25 GBq, trans-
femoral catheter 
single dose of resin microspheres, mean 
activity 2.16 GBq, delivered by a perma-
nent hepatic port 
single dose of resin microspheres, 
median activity 1.79 GBq 
Comparator systemic chemotherapy 
 (5-fluorouracil 425mg/m2/day +  
+leucovorin 20 mg/m2/day for 5 
consecutive days every 4 weeks) 
HAC  
(12 day cycles of 0.3 mg/kg/day floxu-
ridine for 18 cycles) 
systemic chemotherapy  
(5-fluorouracil 300mg/m2/days for 
14 consecutive days every 3 weeks) 
Study design RCT, phase II RCT, phase III RCT, open-label, phase III 
Number of patients 
randomized  
21, I 11 vs C 10 70, I 36 vs C 34  44, I 21 vs C 23 
Mean age of patients 
(years) 
I 64 vs C 65  I 59 vs C 62  I 62 vs C 62 
Patient characteristics  
 
male: I 91% vs C 80% 
extrahepatic metastases: I 18% vs 
C 30% 
male: I 78% vs C 76% 
previous chemotherapy: I 15% vs C 14% 
  
male: I 48% vs C 78% 
previous chemotherapy: I 100% vs 
C 100% 
 
Inclusion liver metastases from CRC ± ex-
trahepatic disease not treatable 
with resection or locally ablative 
therapy, WHO performance sta-
tus <3 
liver metastases from CRC not treatable 
with resection or locally ablative therapy, 
WHO performance status <3, previous 
systemic chemotherapy for the treatment 
of metastases was allowed 
liver metastases from CRC not 
treatable with resection or locally 
ablative therapy, resistant or intol-
erant to standard chemotherapy 
(FU, oxaliplatin, and irinotecan), 
ECOG PS<3,  
Exclusion previously treated metastases, cir-
rhosis, portal hypertension, cen-
tral nervous system metastases 
extrahepatic disease, previous radiother-
apy to the liver, cirrhosis 
extrahepatic disease, liver cirrhosis 
>Child-Pugh B, liver abscess, par-
tial/total thrombosis of the portal 
vein, prior HAC with fluorouracil, 
floxuridine or other chemothera-
peutic regimens 
Median Follow up NR Minimum follow-up of 3.5 years 25 months 
Results    
Median survival (mon-
ths) 
I 29.4 months vs C 12.8 months 
HR = 0.33 
95%CI 0.12 to 0.91, p=0.025 
I 17.0 months vs C 15.9 months 
HR = 1.41 
95%CI 0.86 to 2.34, p= 0.18 
I 10.0 months vs C 7.3 months  
HR =0.92,  
95%CI 0.47 to 1.78, p = 0.80 
Survival rate (%) NR 1 year: I 72% vs C 68% 
2-years: I 39% vs C 29% 
3-years: I 17% vs C 6% 
5-years: I 3.5% vs C 0% 
NR 
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Author, Year  
[Reference]  
Van Hazel 2004 [37] Gray 2001 [38] Hendlisz 2010 [39] 
RECIST non standardized criteria 2 
 
RECIST Tumour response 
measured by tumour 
area (criteria used) CR: I 0% vs C 0% 
PR: I 73% vs C 0% 
SD: I 27% vs C 60% 
PD: I 0% vs C 40% 
Comparison between groups 
p<0.001 
CR: I 6% vs C 0% 
PR: I 39% vs C 18% 
SD: I 36% C 38% 
PD: I 8% vs C 24% 
Difference between groups p=0.01 
  CR: I 0% vs C 0% 
PR: I 10% vs C 0% (p=0.22) 
SD: I 76% vs C 35% (p=0.001) 
PD: I 10% vs C 61% 
Non-evaluable: I 5% vs C 4% 
Tumour response 
measured by CEA 
NR CR: I 42% vs C 26% 
PR: I 31% vs C 21% 
SD: I 6% vs C 29% 
PD: I 3% vs C 18%3 
NR 
Median time to hepatic 
disease progression 
(months) 
NR log-rank measured for tumour area:  
p<0.014 
I 5.5 months vs C 2.1 months 
HR = 0.38  
95%CI 0.20 to 0.72; p = 0.003 
Median time to tumour  
progression (months) 
I 18.6 months vs C 3.6 months, 
p<0.0005 
NR I 4.5 months vs C 2.1 months 
HR = 0.51 
95%CI 0.28 to 0.94, p = 0.03 
QoL at 3 months:  patient reported 
(FLIC questionnaire): no differ-
ences between groups, p=0.96 
Physician reported (Spitzer index): 
no difference, p=0.98 
3-monthly intervals: self Assessment Scale 
by Priestmann and Baum: no significant 
differences between groups 
NR 
Treatment related 
deaths, % (number of 
events) 
I 9% (1/11 pts)  vs C 0% pts 
 
0% 0% 
Overall AEs NR NR NR 
Grade 1 – 2, %  NR liver function tests (number of events): I 
300  vs C 207  
nausea/diarrhoea: I 44% vs C 32%  
NR 
Grade ≥3, %  overall (number of events):  I 13 vs 
C 5 
cirrhosis: I 9% vs C 0%  
nau-
sea/vomiting/gastritis/diarrhoea/
mucositis: I 9% -36% vs C 10%  
granulocytopenia: I 27% vs C 0% 
overall (number of events): I 23 vs C 23  
elevated liver enzymes:  I 3 -39% vs C 0% 
35%  
nausea/vomiting/diarrhoea: I 0% vs C 3% 
Hb: I 0% vs C 3%  
overall I 5% vs C 27%  
Notes once protocol treatment ceased, 
further cancer-specific treatment, 
including non-protocol chemo-
therapy, was allowed to best 
manage patient care 
initially designed for 95 pts, but only 74 
pts were enrolled, study therefore under-
powered for original primary outcome 
(survival), changed to response and time 
to disease progression 
Once protocol treatment ceased, further 
cancer-specific treatment, including non-
protocol chemotherapy was allowed 
10 patients cross-over to SIR treat-
ment, 6 patients from the control 
group received further therapies 
(cetuximab + chemotherapy, che-
motherapy alone), 9 patients in the 
intervention group received further 
treatment (e.g. cetuximab + che-
motherapy, chemotherapy alone) 
Abbreviations used: GBq = Giga Becquerel, ECOG = Eastern Cooperative Oncology Group, PS = Performance Sta-
tus, NR = not reported, CI = confidence interval, WHO = World Health Organisation, PS = performance status, 
RECIST = Response Evaluation Criteria In Solid Tumors, HR = Hazard ratio 
 
                                                             
2 PR: decrease of tumour size ≥50%, CR: disappearance of all tumour lesions, PD: increase in cross-sectional tu-
mour area, by 25% or more over the nadir, development of new lesions in the liver ; NC: decrease in tumour vol-
ume 
3 CR: decrease in serum CEA into the normal range, PR: decrease of serum CEA by ≥50% 
4 Measured as an increase in cross-sectional tumour area/volume by ≥25%, development of new liver lesions, in-
crease in serum CEA by ≥25% over nadir 
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Table 4.1-4: Uncontrolled studies for safety of SIRT for mCRC  
Author, Year [Reference] Cosimelli 2010 [40] Chua 2010 [41] Mulcahy 2009 [42] 
Country Italy Australia USA 
Sponsor SIR-Spheres provided by Sirtex NR one author acts as an advisor to 
MDS Nordion 
Study period May 2005 – August 2007 March 2006 - May 2009 2003 - 2007 
Intervention  resin microspheres resin microspheres glass microspheres 
Indication salvage therapy salvage therapy salvage therapy 
Administration of inter-
vention 
single dose, median activity 1.7 
GBq 
mean activity 1.8 GBq mean number of treatments 1.9, 
median activity 2.37 GBy 
Study design prospective, multi-centre, phase II prospective database collection open-label, expanded use protocol
Number of patients  50 140 72 
Mean age of patients    
(years) 
64  64  61  
Patient characteristics 
 
male: 74% 
previous chemotherapy: 100% 
male: 63% 
Previous chemotherapy: 94% 
male: 65% 
previous chemotherapy: 94% 
Inclusion unresectable CRC liver metastases, 
limited extrahepatic disease, pro-
gressive liver disease following sys-
temic standard chemotherapy, 
ECOG PS ≤2 
unresectable CRC liver metastases, 
ECOG PS ≤2, prior/concomitant chemo-
therapy allowed 
liver-dominant unresectable CRC 
metastases, ECOG PS ≤2 
Exclusion previous HAC NR significant extrahepatic disease, 
life expectancy <3 months 
Median Follow-up  11 months 9 months 26.2 months 
Outcome     
Median overall survival 
(months)  
12.6 months  
(95%CI 7.0 to 18.3 months) 
9 months 
 (95%CI 6.4 to 11.3 months) 
14.5 months 
 (95%CI 9.6 to 21.9 months) 
Survival rate (%) 1-year: 50% 
2-years: 20% 
1-year survival rate: 42% 
2-year survival rate 22% 
3-year survival rate 20% 
5 year survival rate: 30% (from 
time of cancer diagnosis) 
RECIST RECIST WHO Tumour response meas-
ured by tumour area (cri-
teria used)  
 
CR 2% 
PR 22% 
SD 24% 
PD 44% 
CR 1% 
PR 31%  
SD 31% 
PD 37% 
PR 40% 
SD 45% 
PD 15% 
 
 
Median time to hepatic  
disease progression 
2.8 months  
 
NR 15.4 months (95% CI 5.4 to 18 
months) 
Median time to tumour 
progression 
3.7 months 
 (95%CI 2.6 to 4.9 months) 
NR NR 
QoL anxiety levels were significantly 
reduced (p<0.01) at 6 week fol-
low-up 
NR NR 
Treatment related deaths 
(%) 
2 (4%) probably treatment related 
deaths  
0 0 
Overall AEs NR intestinal ulceration: 1%, abdominal 
pain: 14% 
NR 
Grade 1 -2  total: 22% 
leucocytosis: 2%   
jaun-
dice/nausea/fatigue/fever/chronic 
pain: 2%-10% 
gastrointestinal ulcers: 4% 
NR fatigue/abdominal 
pain/nausea/fever/diarrhoea 4% -
61%  
 gastrointestinal ulceration 1% 
Grade ≥3  0% NR elevated liver enzymes: 6% - 13%
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Author, Year [Reference] Cosimelli 2010 [40] Chua 2010 [41] Mulcahy 2009 [42] 
Notes 14 pts received subsequent chemo-
therapy, downstaging enabling re-
section 4% 
34% had concomitant or post radioem-
bolisation chemotherapy after SIRT 
Single factor for better response was 
chemo SIRT 
 
Abbreviations used: GBq = Giga Becquerel, ECOG PS = Eastern Cooperative Oncology Group, PS = Performance 
Status, NR = not reported, CI = confidence interval, WHO = World Health Organisation, RECIST = Response 
Evaluation Criteria In Solid Tumors 
4.2 Efficacy 
HCC: 
2 trials were found which both assessed glass microspheres for the treatment 
of non-resectable HCC (see table 4.1.-1) [30, 31]. Carr et al. [30] compared in 
two sequential cohorts TheraSphere® to TACE with cisplatin and emboliz-
ing particles. Median OS was significantly improved in the SIRT group (I 
11.5 months vs C 8.5 months, p< 0.05). But the study suffers from methodo-
logical weaknesses and even the authors themselves mention that the statis-
tically significant difference in OS is most likely explained by differences in 
baseline characteristics with patients allocated to the SIRT group having 
milder disease than those in the control group. Tumour response showed in-
ferior results for SIRT. 
QoL outcomes were assessed in a small group of patients (I 14 pts vs C 14 
pts) [31] comparing glass-microspheres to HAC. Functional well-being, as 
well as overall health related QoL (HrQL) at 3 months showed improved 
outcomes for patients treated with microspheres. After 6 months, however, 
only the positive effective on functional well-being persisted in patients 
treated with SIRT (p<0.04). But due to the small sample size, these findings 
have to be interpreted with caution.  
Furthermore, 5 uncontrolled studies [32-36] provide limited evidence on ef-
ficacy of SIRT for the treatment of HCCs (see table 4.1-2). In the 4 studies 
with glass-microspheres, median OS varied substantially as results between 
2.5 months and 47 months were found and outcomes for tumour response 
differed too. But these discrepancies can be explained as these numbers rep-
resent results for rather heterogeneous patients (e.g. different tumour stage, 
± extrahepatic disease). The only study [36] with SIR-Spheres® showed a 
median OS of 9.6 months.  
2 studies using 
TheraSphere® 
SIRT in comparison to 
TACE in study of low 
quality 
improvement of OS, but 
not for tumour response 
QoL was outcome in 
study with small sample 
size: only partly 
improved 
uncontrolled studies 
provide limited evidence  
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mCRC:  
Overall 3 RCTs with SIR-Spheres® were included in this report [37-39]. Two 
trials, where the majority of patients received SIRT as first-line therapy [37, 
38], showed somehow varying results (see table 4.1-3). The study conducted 
by van Hazel [37] comprised only 21 patients and showed improvements in 
median OS for patients treated with SIRT + chemotherapy in comparison to 
patients treated with systemic chemotherapy only (HR=0.33, p=0.025). In 
contrast, the other study [38] did not demonstrate favourable results for OS 
in the SIRT group. But similarities were found for outcome measures such 
as tumour response and time to (hepatic) disease progression, where, for ex-
ample, a partial response was achieved more often after the delivery of SIR-
Spheres® (I 39%-73% vs C 0%-18%). Both studies report statistically signifi-
cant differences in TTP in favour of patients treated with SIRT. However, 
when compared to systemic chemotherapy or HAC, neither trial  demon-
strated any difference in QoL, indicating that, if QoL is not improved, addi-
tion of SIRT does at least not worsen QoL.  
However, the trial is open to criticism, since, in addition to the small sample 
size, the chemotherapy regimen used in the van Hazel trial no longer reflects 
standard chemotherapy [37]. Furthermore, patients in both RCTs received 
non-protocol chemotherapy once protocol treatment ceased. Also, extra-
hepatic disease is generally regarded as exclusion criterion for the delivery 
of SIRT [10, 12, 20], but one of the trials incorporated patients with disease 
outside the liver [37]. Moreover, the trial conducted by Gray et al. [38] was 
initially designed to enrol 95 patients, but due to slow accrual only 74 pa-
tients finally entered the trial. Therefore, the initial primary outcome, OS, 
was underpowered and was thus changed to tumour response and TTP. 
Hendlisz et al. [39] evaluated SIR-Spheres® + 5-fluorouracil (5-FU) in pati-
ents with unresectable liver metastases resistant or intolerant to standard 
chemotherapy in comparison to 5-FU only.  With a difference of only 2.7 
months, OS was not statistically significant, but as in the trials mentioned 
above, better results for SIRT + chemotherapy were found for TTP. No dif-
ference was found for partial responses (p=0.22), but disease control rates 
(PR + SD) were improved for patients receiving both, i.e. SIRT and chemo-
therapy, compared to patients treated with chemotherapy alone. (p=0.001). 
Nonetheless, these numbers have to be interpreted with caution, since 10 pa-
tients crossed-over to the SIRT group, and, overall, 15 patients received fur-
ther therapies.  
Some additional evidence might be derived from 3 uncontrolled trials [40-
42] which were primarily included for the safety analysis (see table 4.1-4). As 
none of them are of a comparative study design, no final conclusions on effi-
cacy can be drawn. Overall, 262 previously treated patients were either treat-
ed with glass or resin-microspheres. When SIR-Spheres® [40, 41]  were used, 
median OS ranged from 9 to 12.6 months; TTP was about 4 months [40]. PR 
was seen in 22% [40] to 31% [41]. One study reports additionally that anxi-
ety levels were significantly reduced after 6 weeks [40]. The only study 
where  TheraSphere® was used for the treatment of  mCRC [42], reported a 
median OS of 14.5 months and PR was observed in 40% of all patients.   
3 RCTs evaluating SIR-
Spheres® as 1st-line 
therapy and salvage 
therapy 
2 studies for 1st –line 
therapy 
differing comparators, 
results for OS varied 
similar results for 
tumour response and 
time to disease 
progression 
 
but chemotherapy does 
not reflect standard 
therapy anymore 
additional, non-protocol 
chemotherapy was 
allowed 
for salvage therapy: 1 
RCT 
no difference for OS, 
improved TTP and 
disease control rate 
additional evidence 
from 3 uncontrolled 
studies 
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4.3 Safety 
HCC 
Safety-related outcomes were only reported in the uncontrolled studies (see 
table 4.1-2). In the 4 studies which used glass-microspheres [32-35] grade 1/2 
AEs occurred in up to 77% of patients [33].The most common AEs  were el-
evated liver enzymes, fatigue and abdominal pain. One study reported, that 
out of 108 patients, 1 patient (i.e. 1%) had died due to treatment-related AEs 
[32]. Most common AEs of grade ≥3 were liver dysfunctions which occurred 
in 2% - 26%, but these differences might be explained due to dissimilarities 
between the study populations (e.g. ± liver cirrhosis). Lymphopenia was re-
ported in one study [34] in 11% to 60% of patients.  
Lau et al. [36] investigated resin-microspheres for HCC and also reported 1 
treatment-related death (=1%). Nausea, vomiting and abdominal pain of 
any grade were each seen in 17%; higher grade AEs were not reported.  
mCRC: 
Overall 6 studies (3 RCTs, 3 uncontrolled studies) reported safety outcomes 
for patients with mCRC treated with SIRT (glass and resin) (see table 4.1-3 
und 4.1-4) [37-42]. All but one [42] used SIR-Spheres®. 
Within the RCTs, 1 treatment–related death due to sepsis (=9%, 1 out of 11 
patients) was observed [37]. The most common adverse events of higher 
grades were liver dysfunctions which occurred in 3% to 39% in the SIRT 
group and in 0% to 35% in the control group. Other, non-hepatic AEs of 
grade ≥ 3 included diarrhoea (I 18% vs C 10%) and vomiting/nausea (I 9% 
vs C 10%). Because all 3 RCTs  also allowed further non-protocol therapy it 
is difficult to clearly state which AEs are attributable to SIRT and which to 
chemotherapies.  
Gastrointestinal ulcerations in uncontrolled studies which used SIR-
Spheres® were seen in up to 4%. Cosimelli et al. [40] reported 2 deaths pos-
sibly related to the therapy: one due to kidney failure and the other due to 
liver failure [40]. AEs of grade ≥3 were either not reported or did not occur.  
Grade 1+2 AEs in the only study with TheraSphere® [42] were reported in 
61%. Most common AEs of grade ≥3 were elevated liver enzymes (13%).  
 
HCC: grade 1+2 AEs in 
77% 
1% treatment-related 
deaths, most common 
AEs grade ≥3: liver 
dysfunction 
AEs from 6 studies 
overall 
grade ≥3 liver 
dysfunctions most 
common 
others: diarrhoea, 
nausea 
uncontrolled studies 
reported 2 treatment-
related deaths (liver-
/kidney failure)  
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5 Quality of evidence 
The GRADE approach was used to assess the quality of evidence [43]. The 
GRADE system classifies the quality of evidence in one of four grades: 
 High quality: further research is very unlikely to change our confi-
dence in the estimate of effect  
 Moderate quality: further research is likely to have an important im-
pact on our confidence in the estimate of effect and may change the 
estimates 
 Low quality: further research is very likely to have an important im-
pact on our confidence in the estimate of effect and is likely to change 
the estimate 
 Very low quality: any estimate of effect is very uncertain.  
The GRADE approach was applied to the research question and is displayed 
in table 5.1. and 5.2. As efficacy outcomes for HCC were only found for The-
raSphere®, safety outcomes were only included for those studies which as-
sessed glass-microspheres. Similarly, because all RCTs on SIRT for mCRC 
had used SIR-Spheres®, only safety outcomes of those studies which had 
used the resin-microspheres were incorporated in the tables.  
For the treatment of HCC, the overall strength of evidence for TheraSphere® 
is very low; the one for safety is good. The strength of evidence for SIR-
Spheres® for mCRC is overall low; the one for safety is good.  
 
GRADE approach for 
quality of evidence   
Selective internal radiotherapy 
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Table 5-1: Evidence profile for comparative efficacy and safety for SIRT (TheraSphere®) for HCC 
No of stud-
ies/patients 
Design Limitations Consis-
tency of 
results 
Directness Effect size Other modifying 
factors 
Strength of 
evidence 
Outcome: median survival 
1/790 sequential 
cohort study 
serious limi-
tations1 
- yes  I (99 pts) 11.5 months vs C (691 pts) 
8.5 months,  p< 0.05 
- very low 
Outcome: time to disease progression 
- - - - - - - - 
Outcome: tumour response 
1/790 
 
sequential  
cohort study 
serious limi-
tations1 
- yes CR: I 3% vs C 5% 
PR: I 38% vs C 55% 
SD: I 35% vs C 29% 
PD: I 23% vs C 11% 
- very low 
Outcome: QoL  
1/28 prospective 
non-
randomized 
some limi-
tations2 
- yes some improvements (HrQL and 
functional well-being) after 3 
months 
after 6 months: only for functional 
well-being 
sparse data very low 
Outcome (safety): treatment related deaths 
4/697 prospective, 
uncontrolled 
no serious  
limitations 
yes yes 1% - good 
Outcome (safety):  adverse events grade ≥3   
4/697 prospective 
uncontrolled 
no serious 
limitations 
yes yes hepatic: 2% - 26% 
non-hepatic AEs:1% - 60% 
heterogeneous 
population 
good 
1= baseline characteristics not balanced, patient recruitment during different time periods, follow-up period not re-
ported 
2= no information whether investigators were blinded, possible selection bias, median follow-up not reported 
 
 
 
Table 5-2: Evidence profile: comparative efficacy and safety of SIRT (SIR –Spheres®) for mCRC 
No of 
stud-
ies/patien
ts 
Design Limita-
tions 
Consis-
tency of 
results 
Direct-
ness 
Effect size Other modifying factors* Strength of ev-
idence 
Outcome 1st line: median survival 
2/91 RCTs no seri-
ous limi-
tations 
no yes I 29.4 months vs C 12.8 months 
 (95%CI 0.12 – 0.91, P=0.025) in 21 
pts 
 
I 17 months vs C 15.9 months 
(95%CI 0.86 to 2.34), p=0.18) in 70 
pts 
sparse data/imprecise results, 
other confounding factors, un-
derpowered for OS 
low 
 Outcome salvage: median survival  
1/44 RCT some 
limita-
tions1 
- yes I 10.0 months vs C 7.3 months  
(95%CI 0.47 to 1.78, p = 0.80) 
sparse data/imprecise results, 
other confounding factors 
very low 
Outcome 1st-line: time to tumour progression 
1/21 RCT no seri-
ous limi-
tations 
- yes I 18.6 months vs C 3.6 months, 
p<0.0005 
sparse data, other confounding 
factors 
low 
Outcome salvage: time to tumour progression 
1/44 RCT some 
limita-
tions1 
- yes I 4.5 months vs C 2.1 months, 
p=0.03 
sparse data/imprecise results, 
other confounding factors 
very low 
Quality of evidence 
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Outcome 1st-line: tumour response  
2/91 RCTs no seri-
ous limi-
tations 
yes yes CR: I 0-6% vs C 0% 
PR: I 39-73% vs C 0-18% 
SD: I 27-36% vs C 38-60% 
PD: I 0-8% vs C 24-40% 
sparse data, other confounding 
factors, limited external valid-
ity 
  
moderate 
Outcome salvage: tumour response  
1/44 RCT some 
limita-
tions1 
- yes CR: I 0% vs C 0% 
PR: I 10% vs C 0% 
SD: I 76% vs C 35% 
PD: I 10% vs C 61% 
sparse data, other confounding 
factors 
very low 
Outcome 1st line: QoL 
2/91 RCTs no seri-
ous limi-
tations 
yes yes no difference between I and C sparse data, other confounding 
factors 
moderate 
Outcome salvage: QoL 
-  - - - - - - - 
Outcome (safety): treatment related deaths 
3/135 RCTs no seri-
ous limi-
tations –  
serious 
limita-
tions1 
yes yes I 0% - 9% vs C 0% other confounding factors moderate- good
2/190 prospec-
tive, un-
controlled 
no seri-
ous limi-
tations 
yes yes 0% - 4%  - good 
Outcome (safety):  adverse events grade ≥3   
3/135 RCTs no seri-
ous limi-
tations –  
some lim-
itations1 
yes yes hepatic: I 3% -39% vs C 0% - 35% 
extra-hepatic: 0% -36% vs C 0% -
10% 
other confounding factors moderate -good
1/50 prospec-
tive, un-
controlled 
no seri-
ous limi-
tations 
- - hepatic: 0% 
non-hepatic: 0% 
sparse data moderate 
 
1= unclear allocation concealment, no information about blinding of investigators, unclear ITT 
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6 Discussion 
Even though SIRT using Y-90 - microspheres is the oldest transarterial ther-
apy which has been described for the treatment of liver tumours, its use has 
only increased during the last decade [12]. Even though SIRT is most often 
used for HCC and liver metastases from CRC, several other cancers such as 
metastases of breast cancer or neuroendocrine tumours or cholangiocarci-
nomas might also be treated with SIRT. Nonetheless, even within the two 
main indications, SIRT might be used in various setting such as 1st- line 
therapy, as bridge-to-transplant or as salvage therapy. In spite of the various 
possible indications and a plethora of studies, there are a surprisingly few 
controlled trials. 
As all comparative trials for mCRC used SIR-Spheres®, judgements on effi-
cacy can only be made for resin-microspheres. Even though 3 RCTs were 
found which assessed SIR-Spheres® for mCRC [37-39], a conclusive judge-
ment on efficacy is difficult, since, in addition to some methodological con-
cerns, these trials are rather heterogeneous, because settings, populations 
and comparators varied. Consequently, the results for different outcomes are 
ambiguous.  Indeed,  one study showed significantly improved outcomes for 
median OS [37] whereas 2 other trials, one using SIRT as 1st-line therapy 
[38], the other as salvage therapy [39], found no differences. Clear conclu-
sions on the effect of SIRT on OS are also hampered as patients were al-
lowed to receive non-protocol chemotherapy once protocol treatment ceased, 
or patients crossed-over to SIRT therapy. On the other hand, for outcomes, 
such as tumour response and progression, somehow consistent results, fa-
vouring patients treated with SIR-Spheres® were found. Likewise, there is 
some indication that if QoL is not improved, addition of SIRT to other ther-
apies at least does not compromise QoL. But criticism can be expressed, as, 
for example, no data on the efficacy of SIRT in comparison to current che-
motherapy regimens for the treatment of mCRC exist [11] as 2 trials [37, 39] 
used a chemotherapy regimen which cannot be considered as standard-
therapy any longer. In addition, extrahepatic disease is generally regarded as 
an exclusion criterion for the delivery of SIRT [10, 12, 20], but one of the 
trials incorporated patients with disease outside the liver [37], a fact which 
might not impact on tumour response but might distort outcomes such as 
QoL or OS.   
Data on efficacy of SIRT for HCC was only found for TheraSphere® [30, 31]. 
The available comparative evidence from 2 studies of diminished methodo-
logical quality and with small numbers of patients is rather weak. Therefore, 
a definite statement on efficacy is currently not possible.   
Regarding safety, it seems that careful patient selection and an extensive 
pre-treatment work-up, allow the frequency of serious adverse events to be 
minimized (see chapter 1.2.). The majority of AEs associated with SIRT 
were of grade 1 or 2. More severe AEs, include treatment-related deaths (in 
1%- 9%). More frequent were liver dysfunctions: those of grade≥3 occurred 
in the controlled trials in 39% of patients in the SIRT group in comparison 
to 35% in the control group. The uncontrolled studies report liver dysfunc-
tions in up to 26%. Radiation-induced, sometimes life threatening AEs such 
as radiation pneumonitis/cholecystitis or gastrointestinal ulcerations were 
reported infrequently in up to 4%.  
SIRT oldest transarterial 
therapy, but use 
increased only recently 
for many tumours and 
indications but 
controlled trials rare 
judgements on SIRT for 
mCRC only for SIR-
Spheres® 
different indications and 
comparators 
despite 3 RCTs, 
judgements on efficacy 
difficult, because 
different results for OS, 
no comparison to state-
of-the art 
chemotherapies, 
further chemotherapies 
were allowed, cross-over 
some evidence for 
improved outcomes 
such as tumour response 
for HCC, only studies 
using TheraSphere® 
but due to weak 
evidence, definite 
statement on efficacy 
not possible 
most common AEs: liver 
dysfunctions 
pneumonitits, 
cholezystitis/ulcerations 
in 4% 
Selective internal radiotherapy 
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The lack of unequivocal evidence is also reflected in differing recommenda-
tions by expert groups [7, 8, 19, 44, 45] and institutions [11, 16]. Therefore, 
high-quality studies with comparators relevant to daily practice are needed 
to clearly define the role of SIRT for the treatment of various liver tumours 
[7, 8, 26].  
But in fact, many trials are on-going [25, 46]: examples for SIR-Spheres® in-
clude the FOXFIRE trial (until December 2014), an independent, investiga-
tor-led trial, which will compare 1st-line systemic chemotherapy in addition 
to SIR-Spheres®  with systemic chemotherapy alone [47], or, for the same in-
dication, the SIRFLOX trial (estimated study completion date December 
2012) [48]. For TheraSphere®, on the other hand, only one RCT 
(NCT00109954) was found on ClinicalTrials.gov with the intention of com-
paring SIRT with TACE, but no information is given about when results can 
be expected. This comparison is of great interest, as due to some overlap in 
patient eligibility between SIRT and TACE, it is unclear how to choose be-
tween SIRT and TACE. But some authors suggest that SIRT might be pre-
ferred over TACE in patients with branch or lobar portal vein thrombus [7, 
49]. 
Concerning cost-effectiveness, a report published by the Australian “Medi-
cal Services Advisory Committee“ had modelled cost-effectiveness of SIR-
Spheres®  but due to the surrounding uncertainties (no comparison to cur-
rent treatment regimens, impact on OS) no precise estimated were possible 
[11]. The documents submitted to the MoH state that some cost savings 
might be associated with SIRT as this intervention usually requires fewer 
treatment sessions and can thus reduce hospitals stay in comparison to other 
treatment options (e.g. TACE).  
Limitations of our study might be that due to the inclusion criteria, many 
studies reporting outcomes on SIRT were not considered in this review. 
However, as it is rather unlikely that any relevant comparative trial for effi-
cacy has been missed, we are confident with our estimates on efficacy. Re-
garding safety issues, the limitation to prospective studies comprising only 
≥ 50 patients seems to be justified for the very short time-frame in which we 
had to operate. But it can also be considered a means to improve the quality 
of evidence included, as only centres which perform SIRT interventions fre-
quently might be able to accrue these numbers of patients. Retrospective 
studies, even with large sample sizes, were excluded due to methodological 
concerns.  
In summary, there are some indications that selected patients suffering from 
mCRC can benefit from SIR-Spheres®. In the context of HCC, despite an 
acceptable safety profile, the efficacy of SIRT currently remains unknown.  
 
 
 
 
 
 
 
 
conflicting evidence 
reflected in differing 
recommendations by 
expert groups 
several on-going studies 
for SIR-Spheres® 
only 1 phase III study for 
TheraSphere® 
no precise cost-
effectiveness analyses 
available 
limitations of this report 
indications for efficacy 
of SIR-Spheres® for 
mCRC, no conclusive 
judgment for 
TheraSphere® for HCC 
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7 Recommendation 
Table 7-1 and 7-2 represent the scheme on which the recommendation is 
based. The option chosen is marked.  
Table 7-1: Scheme for recommendation based on the evidence available for SIRT 
(TheraSphere®) for the treatment of HCC 
  Inclusion in the catalogue of benefits is recommended.   
  Inclusion in the catalogue of benefits is recommended with re-strictions. 
X  Inclusion in the catalogue of benefits is currently not recom-mended. 
  Inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The available evidence is currently not sufficient to accurately assess effi-
cacy and safety of SIRT using TheraSphere® for the treatment of HCC (un-
resectable, unablatable) in comparison to other available treatment options 
(TACE, HAC, Sorafenib, best supportive care). A re-evaluation is recom-
mended, but it remains unknown when results of high-quality trials will be-
come available.  
Table 7-2: Scheme for recommendation based on the evidence available for SIRT 
(SIR-Spheres®) for the treatment of mCRC 
  Inclusion in the catalogue of benefits is recommended.   
X  Inclusion in the catalogue of benefits is recommended with re-
strictions. 
  Inclusion in the catalogue of benefits is currently not recom-
mended. 
  Inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The available evidence indicates that SIRT using SIR-Spheres® for the 
treatment of mCRC (unresectable, unablatable) is more efficacious than/ as 
safe as other available treatment options (HAC,  systemic chemotherapy 
with 5-FU/leucovorin) under specific circumstances (careful patient selec-
tion, multidisciplinary team, selected centres), but new studies will probably 
change our effect estimates. Therefore, an inclusion in the catalogue of bene-
fits is recommended with restrictions and a re-evaluation is recommended in 
2015, after completion of the SIRFLOX/FOXFIRE trials.  
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8 Appendix 
Cochrane Suchstrategie am 31.Ja¨nner 2011 
#1 MeSH descriptor Liver Neoplasms explode all trees 
#2 liver NEAR/3 cancer* 
#3 "hepatic neoplasm" 
#4 "hepatic neoplasms" 
#5 "hepatic cancer" 
#6 "hepatic cancers" 
#7 "liver metastasis" 
#8 liver metastases 
#9 "hepatic metastasis" 
#10 "hepatic metastases" 
#11 metastas*s NEAR/3 liver 
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 
OR #11) 
#13 "Selective internal radiation therapy" 
#14 "Selective internal radiotherapy" 
#15 "Selected internal radiation therapy" 
#16 "Selected internal radiotherapy" 
#17 SIRT 
#18 SIR-Sphere* 
#19 SIRTex 
#20 Therasphere* 
#21 "radiolabeled microsphere" 
#22 "radiolabelled microsphere" 
#23 "radiolabeled microspheres" 
#24 "radiolabelled microspheres" 
#25 "radio-labeled microsphere" 
#26 "radio-labelled microsphere" 
#27 "radio-labeled microspheres" 
#28 "radio-labelled microspheres" 
#29 MeSH descriptor Yttrium Radioisotopes explode all trees 
#30 "Yttrium 90" 
#31 Yttrium90 
#32 Y90 
#33 "Y 90" 
#34 MeSH descriptor Microspheres explode all trees 
#35 Radioemboli*ation 
#36 Radioisotope* NEAR/5 Therap* 
#37 (#13 OR #14 OR #17 OR #18 OR #19 OR #20 OR #23 OR #24 OR #29 
OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36) 
#38 (#12 AND #37) 
#1 MeSH descriptor Liver Neoplasms explode all trees 
Selective internal radiotherapy 
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#2 liver NEAR/3 cancer* 
#3 "hepatic neoplasm" 
#4 "hepatic neoplasms" 
#5 "hepatic cancer" 
#6 "hepatic cancers" 
#7 "liver metastasis" 
#8 liver metastases 
#9 "hepatic metastasis" 
#10 "hepatic metastases" 
#11 metastas*s NEAR/3 liver 
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 
OR #11) 
#13 "Selective internal radiation therapy" 
#14 "Selective internal radiotherapy" 
#15 "Selected internal radiation therapy" 
#16 "Selected internal radiotherapy" 
#17 SIRT 
#18 SIR-Sphere* 
#19 SIRTex 
#20 Therasphere* 
#21 "radiolabeled microsphere" 
#22 "radiolabelled microsphere" 
#23 "radiolabeled microspheres" 
#24 "radiolabelled microspheres" 
#25 "radio-labeled microsphere" 
#26 "radio-labelled microsphere" 
 58 Hits 
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CRD Suchstrategie am 31.Ja¨nner 2011 
"Selective internal radiation therapy" 
"Selective internal radiotherapy" 
"Selected internal radiotherapy" 
"Selected internal radiation therapy" 
SIRT 
SIR-Sphere* 
SIRTex 
Therasphere* 
"radiolabeled microsphere" 
"radiolabelled microsphere" 
"radiolabelled microspheres" 
"radiolabeled microspheres" 
"radio-labeled microspheres" 
"radio-labeled microsphere" 
"radio-labelled microsphere" 
"radio-labelled microspheres" 
MeSH Yttrium Radioisotopes QUALIFIERS AD TU ST RE EXPLODE 1 2 
"Yttrium 90" 
"Yttrium90" 
"Y 90" 
"Y90" 
MeSH Microspheres EXPLODE 1 
Radioemboli*ation 
Radioembolisation 
Radioembolization 
Radioisotope* NEAR Therap* 
#1 OR #5 OR #6 OR #8 OR #17 OR #18 OR #21 OR #22 OR #25 OR #26 
"Selective internal radiation therapy" 
"Selective internal radiotherapy" 
"Selected internal radiotherapy" 
"Selected internal radiation therapy" 
SIRT 
SIR-Sphere* 
SIRTex 
Therasphere* 
"radiolabeled microsphere" 
"radiolabelled microsphere" 
"radiolabelled microspheres" 
"radiolabeled microspheres" 
"radio-labeled microspheres" 
"radio-labeled microsphere" 
"radio-labelled microsphere" 
"radio-labelled microspheres" 
Selective internal radiotherapy 
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MeSH Yttrium Radioisotopes QUALIFIERS AD TU ST RE EXPLODE 1 2 
"Yttrium 90" 
"Yttrium90" 
"Y 90" 
"Y90" 
MeSH Microspheres EXPLODE 1 
Radioemboli*ation 
Radioembolisation 
Radioembolization 
Radioisotope* NEAR Therap* 
#1 OR #5 OR #6 OR #8 OR #17 OR #18 OR #21 OR #22 OR #25 OR #26 
"Selective internal radiation therapy" 
"Selective internal radiotherapy" 
"Selected internal radiotherapy" 
"Selected internal radiation therapy" 
SIRT 
SIR-Sphere* 
SIRTex 
Therasphere* 
"radiolabeled microsphere" 
"radiolabelled microsphere" 
25 Hits 
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Embase Suchstrategie am 28. Ja¨nner 2011 
#47.  #13 AND #46                                                 734   
#46.  #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR   
#22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 
OR  #29 OR #39 OR #40 OR #41 OR #42 OR #45       
8,638   
#45.  #43 AND #44                                                 398 
#44.  'radioisotope'/exp                                      501,026   
#43. 'yttrium'/exp                                             3,169   
#42.  therasphere*                                                103 
#41.  'radioisotope therapy'/exp                                6,238   
#40.  radioemboli?ation                                           302 
#39.   #35 AND #38                                                 401 
#38.  #36 OR #37                                               24,267   
#37.       microspheres    18,560   
#36.  'microsphere'/exp                                        15,984   
#35.  #31 OR #32 OR #33 OR #34                                  4,023   
#34.  'y 90'                                                      961   
#33.       y90     102 
#32.       yttrium90   12 
#31.  'yttrium 90'/exp                                          3,401   
#29.  'radio-labelled microspheres'                                15 
#28.  'radio-labeled microspheres'                                 22 
#27.  'radiolabelled microspheres'                                189 
#26.  'radiolabeled microspheres'                                 700 
#25.  'radio-labelled microsphere'                                  4 
#24.  'radio-labeled microsphere'                                   6 
#23.  'radiolabelled microsphere'                                  48 
#22.  'radiolabeled microsphere'                                  213 
#20.      sirtex      99 
#19.  'sir-spheres'                                               109 
#18.  'sir-sphere'                                                 16 
#17.  sirt 329 
#16.  'selected internal radiation therapy'                         1 
#15.   'selective internal radiation therapy'                      137 
#14.   'selective internal radiotherapy'                            35 
#13.  #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR 
#9 OR #10 OR #11 OR #12   
148,305   
#12.  metastas* NEAR/4 liver                                   45,345   
#11.  'liver metastasis'/exp                                   25,439   
#10.  'hepatic metastases'                                      4,510   
#9.   'hepatic metastasis'                                      1,930   
#8.   'liver metastases'                                       11,459   
#7.   'liver metastasis'                                       27,561   
#6.     'hepatic neoplasms'                                         535 
#5.  'hepatic neoplasm'                                          180   
Selective internal radiotherapy 
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#4.   liver NEAR/4 cancer*                                    116,892   
#3.   'liver neoplasms'                                         2,628   
#2.     'liver neoplasm'                                            537 
#1.   'liver tumor'/exp                                       133,450   
Appendix 
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Medline Suchstrategie am 28.Ja¨nner 2011 
1     exp Liver Neoplasms/ (105396) 
2 (liver adj3 cancer*).mp. (11207) 
3     hepatic neoplasm*.mp. (555) 
4      hepatic cancer*.mp. (667) 
5      liver metastas#s.mp. (12903) 
6      hepatic metastas#s.mp. (5054) 
7     (metastas#s adj3 liver).mp. (15160) 
8     1 or 2 or 3 or 4 or 5 or 6 or 7 (114494) 
9      Selective internal radiation therapy.mp. (87) 
10      Selective internal radiotherapy.mp. (15) 
11      Selected internal radiation therapy.mp. (1) 
12      SIRT.mp. (202) 
13      SIR-Sphere*.mp. (45) 
14      SIRTex.mp. (7) 
15      Therasphere*.mp. (29) 
16      radiolabel?ed microsphere*.mp. (1015) 
17      radio-label?ed microsphere*.mp. (41) 
18      exp Yttrium Radioisotopes/ (1683) 
19      Yttrium 90.mp. (968) 
20      Yttrium90.mp. (14) 
21      Y90.mp. (104) 
22      Y 90.mp. (203) 
23      19 or 20 or 21 or 22 (1198) 
24     exp Microspheres/ (19054) 
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